XSHE
000403
Market cap1.40bUSD
Oct 09, Last price
9.96CNY
1D
1.22%
1Q
8.03%
Jan 2017
-40.71%
Name
Pacific Shuanglin Bio-pharmacy Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's diverse product portfolio includes a range of vital human blood-derived therapies such as serum albumin, various forms of human immunoglobulin (including specific preparations for rabies, hepatitis B, tetanus, and intravenous human immunoglobulin (PH4)). They also manufacture topical remedies like tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, and dieshangling plasters, alongside general medical gauzes. Beyond current offerings, Pacific Shuanglin is actively engaged in developing advanced biopharmaceutical products, including porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. Furthermore, the company expands its interests to encompass investment, consultation, and technology promotion for pharmaceutical and biotechnology projects. Its broader ventures include real estate development, electronic product information services, and the provision of electricity. The entity adopted its current name, Pacific Shuanglin Bio-pharmacy Co., Ltd., in April 2021, having previously been known as Southern Shuanglin Bio-pharmacy Co., Ltd.
Key people
Shaolan Fu
Co-Chairman of the Board · since 2023
Yehong Wang
Chief Financial Officer · since 2021
Xiankui Rong
General Manager · since 2023
Xiaoying Huang
Deputy General Manager, Director · since 2023
Lan Ye
Deputy General Manager, Director · since 2023
Qunge Zhang
Deputy General Manager · since 2023
Yulin Zhao
Secretary of the Board · since 2019
Haiwang Chen
Director · since 2005
Hao Li
Chairman of the Board · since 2023
Director · since 2024
Jun Luo
Director · since 2018
Wenbin Si
Deputy General Manager, Director · since 2023
Lei Yan
Deputy General Manager, Director · since 2023
Li Yang
Director
Huagang Yuan
Director · since 2023
Jianmin Yuan
Executive Deputy General Manager, Director · since 2009
Zuojun Dong
Independent Director · since 2023
Jun Liu
Independent Director · since 2023
Wenqi Wang
Independent Director · since 2023
Jun Yin
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||